# Prostate Cancer Prostate cancer is currently the most clinically advanced area of Urolithin A oncology research. It is the only cancer type with an active placebo-controlled phase II trial of direct Urolithin A supplementation, and the only one with published human prostate-cancer-specific immune data. The evidence divides naturally by disease setting. Hormone-sensitive disease, castration-resistant disease, and immune modulation each bring different findings. All in vitro and animal findings remain preclinical. Where human evidence exists, it is identified clearly below. ### Hormone-sensitive prostate cancer #### Androgen-receptor suppression Urolithin A has been shown to downregulate androgen-receptor expression and transcriptional activity in androgen-receptor-positive prostate-cancer models. In C4-2B cells, which model androgen-insensitive castration-resistant disease but still retain androgen-receptor relevance, Urolithin A inhibited proliferation and suppressed both androgen-receptor and phospho-AKT signalling. Androgen-receptor-positive cells appeared more sensitive than androgen-receptor-negative cells. That suggests at least part of the effect is androgen-receptor-linked. A pomegranate-fruit-extract trial in men with recurrent prostate cancer also found reductions in 8-OHdG and androgen-receptor expression in prostate tissue. Urolithin A glucuronide was detected more often in the active-treatment arm. This is not a direct Urolithin A trial. It is still relevant because it links prostate-tissue changes to urolithin metabolism in a randomised human setting. #### p53, MDM2, and apoptosis Urolithin A induces apoptosis in prostate-cancer cells through both p53-dependent and p53-independent routes. In LNCaP and 22Rv1 cells, it increased p53 and upregulated p21, PUMA, and NOXA. It also inhibited the interaction between p53 and MDM2, reducing MDM2-mediated p53 degradation. That helps sustain the apoptotic signal. In AR-negative PC3 cells, Urolithin A still induced apoptosis through p14ARF and p21-related signalling. That matters because it suggests activity does not disappear completely in less p53-dependent or androgen-receptor-independent settings. #### Cell-cycle effects Urolithin A also produces G1-phase arrest in prostate-cancer lines. The clearest mechanism is p21 upregulation, confirmed at both mRNA and protein level, with promoter activation shown in luciferase work. Caspase 3 and 7 activation has also been reported. #### Oxidative DNA damage Reduction of oxidative DNA damage is one of the most clinically relevant prostate-cancer themes. This is also why 8-OHdG is the primary endpoint of the active URO-PRO study. Both preclinical work and pomegranate-derived human data suggest Urolithin A may reduce oxidative damage inside prostate tumour tissue. Because oxidative stress contributes to mutagenesis and treatment resistance, this is a meaningful mechanistic endpoint rather than a trivial biomarker. ### Castration-resistant prostate cancer Castration-resistant prostate cancer remains heavily shaped by androgen-receptor signalling, even after testosterone suppression. That makes this setting especially relevant to Urolithin A. #### The AR-V7 resistance problem Urolithin A itself suppresses androgen-receptor signalling. However, the more detailed AR-V7 work has been done with ASR-600, a Urolithin-A-related structural analogue rather than Urolithin A itself. That analogue showed activity against both full-length androgen receptor and AR-V7, enhanced androgen-receptor ubiquitination, and suppressed growth of androgen-receptor-positive castration-resistant models. This is not direct Urolithin A evidence. It still matters because it shows the Urolithin-A scaffold is chemically relevant to one of the biggest resistance problems in advanced prostate cancer. #### AR-dependent and AR-independent pathways In addition to androgen-receptor suppression, Urolithin A also appears to inhibit AKT and mTOR signalling while increasing PTEN expression. That is relevant because PTEN loss and PI3K/AKT pathway activation are common in advanced prostate cancer. This gives Urolithin A a broader biological range than a purely androgen-receptor-focused compound. #### Combination with androgen-deprivation therapy Preclinical discussions suggest that Urolithin A and androgen-deprivation therapy may act on overlapping but not identical survival pathways. That creates a plausible rationale for complementary use. There is still no clinical combination dataset showing whether the effect is additive, synergistic, neutral, or problematic. ### Human evidence — NK-cell activation This is the strongest direct human prostate-cancer-specific evidence for Urolithin A. A published ex vivo study incubated PBMCs from prostate-cancer patients and healthy controls with Urolithin A at physiologically relevant concentrations. At 10 µM, Urolithin A increased NK-cell cytotoxic activity by an average of 23% in prostate-cancer patients. The mechanism involved AhR antagonism. The study also reported reductions in several pro-inflammatory cytokines from patient PBMCs, including fractalkine, IL-8, and MCP-3. This is not an in vivo clinical outcome study. It does show that Urolithin A can modulate immune function in cells derived from prostate-cancer patients at realistic concentrations. ### Active clinical trial — URO-PRO The URO-PRO study is the most important ongoing direct Urolithin A trial in any cancer type. Key features include: * phase II, randomised, placebo-controlled design * men with biopsy-confirmed prostate cancer scheduled for radical prostatectomy * Urolithin A 1000 mg/day versus placebo * treatment for 3 to 6 weeks before surgery * primary endpoint of change in 8-OHdG in tumour tissue * secondary endpoints including cell-cycle gene expression and oxidative-damage markers in benign and adjacent tissue This trial is important because it will provide the first placebo-controlled direct test of whether oral Urolithin A changes prostate tumour biology in humans. ### Pomegranate-extract trials — useful context, but not direct proof Several pomegranate-juice and pomegranate-extract studies in recurrent prostate cancer matter here because Urolithin A is one of the downstream metabolites likely to contribute to the observed effects. These studies have reported PSA-doubling-time changes and tumour-biology signals in some groups. They should not be treated as direct Urolithin A trials. That distinction matters because pomegranate products contain many bioactives, and conversion to Urolithin A varies significantly between individuals. The direct-supplement URO-PRO trial is important partly because it removes that metabotype-related uncertainty. ### What remains unknown Several important questions are still open. * whether Urolithin A changes prostate tumour tissue enough to matter clinically — URO-PRO should help answer part of that * what the best oncology-specific dose really is * whether Urolithin A combines well with enzalutamide, abiraterone, docetaxel, or other standard advanced-disease treatments * whether ex vivo NK-cell activation translates into meaningful in vivo anti-tumour benefit * whether long-term outcomes such as recurrence, metastasis-free survival, or disease-free survival can be improved ### Bottom line Prostate cancer is currently the strongest clinical-development setting for Urolithin A. That is because it combines: * strong preclinical androgen-receptor and apoptosis biology * oxidative-DNA-damage relevance * direct human immune data * and an active placebo-controlled phase II trial Even here, the evidence is not yet practice-changing. It is still investigational. But it is more clinically advanced than the evidence base in any other cancer type studied so far. ### References Urolithin A induces prostate-cancer cell death in p53-dependent and p53-independent manners\ Urolithin A causes p21 up-regulation in prostate-cancer cells\ A natural molecule, Urolithin A, downregulates androgen-receptor activation and suppresses growth of prostate cancer\ Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and AR-V7\ Urolithins as emerging natural compounds targeting castration-resistant prostate cancer\ Urolithin A increases the natural-killer activity of PBMCs in patients with prostate cancer\ A phase II randomised placebo-controlled trial of pomegranate fruit extract in men with recurrent prostate cancer\ Pomegranate juice metabolites, ellagic acid, and Urolithin A in androgen-independent prostate-cancer growth research\ URO-PRO trial listing\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/prostate-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.